Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Effects of ceragenins and conventional antimicrobials on Candida albicans and Staphylococcus aureus mono and multispecies biofilms.

Hacioglu M, Haciosmanoglu E, Birteksoz-Tan AS, Bozkurt-Guzel C, Savage PB.

Diagn Microbiol Infect Dis. 2019 Nov;95(3):114863. doi: 10.1016/j.diagmicrobio.2019.06.014. Epub 2019 Jul 11.

PMID:
31471074
2.

Comparative In Vitro Activities of First and Second-Generation Ceragenins Alone and in Combination with Antibiotics Against Multidrug-Resistant Klebsiella pneumoniae Strains.

Ozbek-Celik B, Damar-Celik D, Mataraci-Kara E, Bozkurt-Guzel C, Savage PB.

Antibiotics (Basel). 2019 Aug 27;8(3). pii: E130. doi: 10.3390/antibiotics8030130.

3.

Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients.

Pereira CS, Pérez-Cabezas B, Ribeiro H, Maia ML, Cardoso MT, Dias AF, Azevedo O, Ferreira MF, Garcia P, Rodrigues E, Castro-Chaves P, Martins E, Aguiar P, Pineda M, Amraoui Y, Fecarotta S, Leão-Teles E, Deng S, Savage PB, Macedo MF.

Front Immunol. 2019 Jun 4;10:1264. doi: 10.3389/fimmu.2019.01264. eCollection 2019.

4.

Effects of the microbicide ceragenin CSA-13 on and properties of Bacillus subtilis spores prepared on two very different media.

Ghosh S, Joseph G, Korza G, He L, Yuan JH, Dong W, Setlow B, Li YQ, Savage PB, Setlow P.

J Appl Microbiol. 2019 Jul;127(1):109-120. doi: 10.1111/jam.14300. Epub 2019 Jun 3.

PMID:
31067345
5.

Use of ceragenins as a potential treatment for urinary tract infections.

Wnorowska U, Piktel E, Durnaś B, Fiedoruk K, Savage PB, Bucki R.

BMC Infect Dis. 2019 May 2;19(1):369. doi: 10.1186/s12879-019-3994-3.

6.

High-affinity anti-glycan antibodies: challenges and strategies.

Polonskaya Z, Savage PB, Finn MG, Teyton L.

Curr Opin Immunol. 2019 Aug;59:65-71. doi: 10.1016/j.coi.2019.03.004. Epub 2019 Apr 28. Review.

PMID:
31029911
7.

Proteomic Analysis of Resistance of Gram-Negative Bacteria to Chlorhexidine and Impacts on Susceptibility to Colistin, Antimicrobial Peptides, and Ceragenins.

Hashemi MM, Holden BS, Coburn J, Taylor MF, Weber S, Hilton B, Zaugg AL, McEwan C, Carson R, Andersen JL, Price JC, Deng S, Savage PB.

Front Microbiol. 2019 Feb 18;10:210. doi: 10.3389/fmicb.2019.00210. eCollection 2019.

8.

In vitro activities of antimicrobial peptides and ceragenins against Legionella pneumophila.

Birteksoz-Tan AS, Zeybek Z, Hacioglu M, Savage PB, Bozkurt-Guzel C.

J Antibiot (Tokyo). 2019 May;72(5):291-297. doi: 10.1038/s41429-019-0148-1. Epub 2019 Feb 12.

PMID:
30755738
9.

Susceptibility of Multidrug-Resistant Bacteria, Isolated from Water and Plants in Nigeria, to Ceragenins.

Hashemi MM, Mmuoegbulam AO, Holden BS, Coburn J, Wilson J, Taylor MF, Reiley J, Baradaran D, Stenquist T, Deng S, Savage PB.

Int J Environ Res Public Health. 2018 Dec 6;15(12). pii: E2758. doi: 10.3390/ijerph15122758.

10.

Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.

Schmid H, Schneidawind C, Jahnke S, Kettemann F, Secker KA, Duerr-Stoerzer S, Keppeler H, Kanz L, Savage PB, Schneidawind D.

Front Immunol. 2018 Aug 6;9:1817. doi: 10.3389/fimmu.2018.01817. eCollection 2018.

11.

A natural killer T-cell subset that protects against airway hyperreactivity.

Chuang YT, Leung K, Chang YJ, DeKruyff RH, Savage PB, Cruse R, Benoit C, Elewaut D, Baumgarth N, Umetsu DT.

J Allergy Clin Immunol. 2019 Feb;143(2):565-576.e7. doi: 10.1016/j.jaci.2018.03.022. Epub 2018 May 29.

PMID:
29852257
12.

Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.

Hacioglu M, Guzel CB, Savage PB, Tan ASB.

Med Mycol. 2019 Apr 1;57(3):291-299. doi: 10.1093/mmy/myy023.

PMID:
29846682
13.

Ceragenin CSA-13 as free molecules and attached to magnetic nanoparticle surfaces induce caspase-dependent apoptosis in human breast cancer cells via disruption of cell oxidative balance.

Piktel E, Prokop I, Wnorowska U, Król G, Cieśluk M, Niemirowicz K, Savage PB, Bucki R.

Oncotarget. 2018 Apr 24;9(31):21904-21920. doi: 10.18632/oncotarget.25105. eCollection 2018 Apr 24.

14.

CSA-90 Promotes Bone Formation and Mitigates Methicillin-resistant Staphylococcus aureus Infection in a Rat Open Fracture Model.

Mills R, Cheng TL, Mikulec K, Peacock L, Isaacs D, Genberg C, Savage PB, Little DG, Schindeler A.

Clin Orthop Relat Res. 2018 Jun;476(6):1311-1323. doi: 10.1097/01.blo.0000533624.79802.e1.

15.

Investigation of the in vitro antifungal and antibiofilm activities of ceragenins CSA-8, CSA-13, CSA-44, CSA-131, and CSA-138 against Candida species.

Bozkurt-Guzel C, Hacioglu M, Savage PB.

Diagn Microbiol Infect Dis. 2018 Aug;91(4):324-330. doi: 10.1016/j.diagmicrobio.2018.03.014. Epub 2018 Mar 28.

PMID:
29680320
16.

Ceragenins are active against drug-resistant Candida auris clinical isolates in planktonic and biofilm forms.

Hashemi MM, Rovig J, Holden BS, Taylor MF, Weber S, Wilson J, Hilton B, Zaugg AL, Ellis SW, Yost CD, Finnegan PM, Kistler CK, Berkow EL, Deng S, Lockhart SR, Peterson M, Savage PB.

J Antimicrob Chemother. 2018 Jun 1;73(6):1537-1545. doi: 10.1093/jac/dky085.

PMID:
29635279
17.

Antibacterial and Antifungal Activities of Poloxamer Micelles Containing Ceragenin CSA-131 on Ciliated Tissues.

Hashemi MM, Holden BS, Taylor MF, Wilson J, Coburn J, Hilton B, Nance T, Gubler S, Genberg C, Deng S, Savage PB.

Molecules. 2018 Mar 7;23(3). pii: E596. doi: 10.3390/molecules23030596.

18.

Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics.

Bucki R, Durnaś B, Wątek M, Piktel E, Cruz K, Wolak P, Savage PB, Janmey PA.

Infect Drug Resist. 2018 Jan 11;11:77-86. doi: 10.2147/IDR.S145337. eCollection 2018.

19.

Preclinical testing of a broad-spectrum antimicrobial endotracheal tube coated with an innate immune synthetic mimic.

Hashemi MM, Rovig J, Bateman J, Holden BS, Modelzelewski T, Gueorguieva I, von Dyck M, Bracken R, Genberg C, Deng S, Savage PB.

J Antimicrob Chemother. 2018 Jan 1;73(1):143-150. doi: 10.1093/jac/dkx347.

20.

Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.

Durnaś B, Piktel E, Wątek M, Wollny T, Góźdź S, Smok-Kalwat J, Niemirowicz K, Savage PB, Bucki R.

BMC Microbiol. 2017 Jul 26;17(1):167. doi: 10.1186/s12866-017-1075-6.

21.

Stiffening of bacteria cells as a first manifestation of bactericidal attack.

Pogoda K, Piktel E, Deptuła P, Savage PB, Lekka M, Bucki R.

Micron. 2017 Oct;101:95-102. doi: 10.1016/j.micron.2017.06.011. Epub 2017 Jun 27.

PMID:
28683405
22.

Antimicrobial ceragenins inhibit biofilms and affect mammalian cell viability and migration in vitro.

Olekson MA, You T, Savage PB, Leung KP.

FEBS Open Bio. 2017 May 22;7(7):953-967. doi: 10.1002/2211-5463.12235. eCollection 2017 Jul.

23.

Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.

Niemirowicz K, Durnaś B, Tokajuk G, Piktel E, Michalak G, Gu X, Kułakowska A, Savage PB, Bucki R.

Sci Rep. 2017 Jul 4;7(1):4610. doi: 10.1038/s41598-017-04653-1.

24.

The search for new sporicidal agents for medical use: where are we?

Piktel E, Pogoda K, Savage PB, Bucki R.

Future Microbiol. 2017 Jul;12:735-737. doi: 10.2217/fmb-2017-0069. Epub 2017 Jun 8. No abstract available.

PMID:
28593804
25.

Susceptibility of Colistin-Resistant, Gram-Negative Bacteria to Antimicrobial Peptides and Ceragenins.

Hashemi MM, Rovig J, Weber S, Hilton B, Forouzan MM, Savage PB.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00292-17. doi: 10.1128/AAC.00292-17. Print 2017 Aug.

26.

Psychosine variants as antigens for natural killer T cells.

Deng S, Kain L, Pereira CS, Mata S, Macedo MF, Bendelac A, Teyton L, Savage PB.

Chem Sci. 2017 Mar 1;8(3):2204-2208. doi: 10.1039/c6sc04218j. Epub 2016 Dec 9.

27.

Sporicidal activity of ceragenin CSA-13 against Bacillus subtilis.

Piktel E, Pogoda K, Roman M, Niemirowicz K, Tokajuk G, Wróblewska M, Szynaka B, Kwiatek WM, Savage PB, Bucki R.

Sci Rep. 2017 Mar 15;7:44452. doi: 10.1038/srep44452.

28.

T cells control the generation of nanomolar-affinity anti-glycan antibodies.

Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay CS, Kaczanowska K, Holt M, McBride R, Palomo V, Self KM, Taylor S, Irimia A, Mehta SR, Dan JM, Brigger M, Crotty S, Schoenberger SP, Paulson JC, Wilson IA, Savage PB, Finn MG, Teyton L.

J Clin Invest. 2017 Apr 3;127(4):1491-1504. doi: 10.1172/JCI91192. Epub 2017 Mar 13.

29.

Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine.

Li B, Siuta M, Bright V, Koktysh D, Matlock BK, Dumas ME, Zhu M, Holt A, Stec D, Deng S, Savage PB, Joyce S, Pham W.

Int J Nanomedicine. 2016 Nov 16;11:6103-6121. eCollection 2016.

30.

Core-shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin LL-37 or selected ceragenins.

Niemirowicz K, Piktel E, Wilczewska AZ, Markiewicz KH, Durnaś B, Wątek M, Puszkarz I, Wróblewska M, Niklińska W, Savage PB, Bucki R.

Int J Nanomedicine. 2016 Oct 19;11:5443-5455. eCollection 2016.

31.

Discrete TCR Binding Kinetics Control Invariant NKT Cell Selection and Central Priming.

Cruz Tleugabulova M, Escalante NK, Deng S, Fieve S, Ereño-Orbea J, Savage PB, Julien JP, Mallevaey T.

J Immunol. 2016 Nov 15;197(10):3959-3969. Epub 2016 Oct 19.

32.

The processing and presentation of lipids and glycolipids to the immune system.

Vartabedian VF, Savage PB, Teyton L.

Immunol Rev. 2016 Jul;272(1):109-19. doi: 10.1111/imr.12431. Review.

33.

Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.

Durnaś B, Wnorowska U, Pogoda K, Deptuła P, Wątek M, Piktel E, Głuszek S, Gu X, Savage PB, Niemirowicz K, Bucki R.

PLoS One. 2016 Jun 17;11(6):e0157242. doi: 10.1371/journal.pone.0157242. eCollection 2016.

34.

Evaluation of the in vitro activity of ceragenins against Trichomonas vaginalis.

Polat ZA, Cetin A, Savage PB.

Acta Parasitol. 2016 Mar;61(2):376-81. doi: 10.1515/ap-2016-0049.

PMID:
27078662
35.

Species Specific Differences of CD1d Oligomer Loading In Vitro.

Paletta D, Fichtner AS, Starick L, Porcelli SA, Savage PB, Herrmann T.

PLoS One. 2015 Nov 24;10(11):e0143449. doi: 10.1371/journal.pone.0143449. eCollection 2015.

36.

CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates.

Vila-Farrés X, Callarisa AE, Gu X, Savage PB, Giralt E, Vila J.

Int J Antimicrob Agents. 2015 Nov;46(5):568-71. doi: 10.1016/j.ijantimicag.2015.08.003. Epub 2015 Sep 7.

PMID:
26395218
37.

Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.

Bucki R, Niemirowicz K, Wnorowska U, Byfield FJ, Piktel E, Wątek M, Janmey PA, Savage PB.

Antimicrob Agents Chemother. 2015 Oct;59(10):6274-82. doi: 10.1128/AAC.00653-15. Epub 2015 Jul 27.

38.

Endogenous ligands of natural killer T cells are alpha-linked glycosylceramides.

Kain L, Costanzo A, Webb B, Holt M, Bendelac A, Savage PB, Teyton L.

Mol Immunol. 2015 Dec;68(2 Pt A):94-7. doi: 10.1016/j.molimm.2015.06.009. Epub 2015 Jul 2. Review.

39.

Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells.

Niemirowicz K, Prokop I, Wilczewska AZ, Wnorowska U, Piktel E, Wątek M, Savage PB, Bucki R.

Int J Nanomedicine. 2015 Jun 4;10:3843-53. doi: 10.2147/IJN.S76104. eCollection 2015.

40.

Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles.

Niemirowicz K, Surel U, Wilczewska AZ, Mystkowska J, Piktel E, Gu X, Namiot Z, Kułakowska A, Savage PB, Bucki R.

J Nanobiotechnology. 2015 May 1;13:32. doi: 10.1186/s12951-015-0093-5.

41.

Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.

Wnorowska U, Niemirowicz K, Myint M, Diamond SL, Wróblewska M, Savage PB, Janmey PA, Bucki R.

Antimicrob Agents Chemother. 2015 Jul;59(7):3808-15. doi: 10.1128/AAC.00421-15. Epub 2015 Apr 13.

42.

The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides.

Kain L, Webb B, Anderson BL, Deng S, Holt M, Costanzo A, Zhao M, Self K, Teyton A, Everett C, Kronenberg M, Zajonc DM, Bendelac A, Savage PB, Teyton L.

Immunity. 2014 Oct 16;41(4):543-54. doi: 10.1016/j.immuni.2014.08.017. Erratum in: Immunity. 2014 Nov 20;41(5):867. Constanzo, Anne [corrected to Costanzo, Anne].

43.

Vaccine development: NKT-cell adjuvants in conjugate.

Savage PB.

Nat Chem Biol. 2014 Nov;10(11):882-3. doi: 10.1038/nchembio.1667. No abstract available.

PMID:
25325698
44.

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination.

Tefit JN, Crabé S, Orlandini B, Nell H, Bendelac A, Deng S, Savage PB, Teyton L, Serra V.

Vaccine. 2014 Oct 21;32(46):6138-45. doi: 10.1016/j.vaccine.2014.08.070. Epub 2014 Sep 13.

45.

Ceragenin mediated selectivity of antimicrobial silver nanoparticles.

Hoppens MA, Sylvester CB, Qureshi AT, Scherr T, Czapski DR, Duran RS, Savage PB, Hayes D.

ACS Appl Mater Interfaces. 2014 Aug 27;6(16):13900-8. doi: 10.1021/am504640f. Epub 2014 Aug 11.

PMID:
25054867
46.

Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients.

Bozkurt-Guzel C, Savage PB, Akcali A, Ozbek-Celik B.

Biomed Res Int. 2014;2014:710273. doi: 10.1155/2014/710273. Epub 2014 Mar 24.

47.

A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses in vivo.

Deng S, Bai L, Reboulet R, Matthew R, Engler DA, Teyton L, Bendelac A, Savage PB.

Chem Sci. 2014 Apr;5(4):1437-1441.

48.

Stimulation of natural killer T cells by glycolipids.

Anderson BL, Teyton L, Bendelac A, Savage PB.

Molecules. 2013 Dec 16;18(12):15662-88. doi: 10.3390/molecules181215662. Review.

49.

Crystal structure of Vδ1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells.

Luoma AM, Castro CD, Mayassi T, Bembinster LA, Bai L, Picard D, Anderson B, Scharf L, Kung JE, Sibener LV, Savage PB, Jabri B, Bendelac A, Adams EJ.

Immunity. 2013 Dec 12;39(6):1032-42. doi: 10.1016/j.immuni.2013.11.001. Epub 2013 Nov 14.

50.

Synthesis of fungal glycolipid asperamide B and investigation of its ability to stimulate natural killer T cells.

Chaudhary V, Albacker LA, Deng S, Chuang YT, Li Y, Umetsu DT, Savage PB.

Org Lett. 2013 Oct 18;15(20):5242-5. doi: 10.1021/ol4024375. Epub 2013 Oct 10.

PMID:
24111801

Supplemental Content

Loading ...
Support Center